Aurora's Response to Curaleaf's Hostile Bid Unveils Earlier Proposals and a $5 Cap
ACB sits 50% above its 52-week low of $2.56.
Summary
Aurora Cannabis responded to Curaleaf's hostile takeover bid, revealing prior proposals and a $5.00 consideration cap, and announced a special committee to review the offer.
Key Events · M&A and Partnerships · ACB
-
Aurora Responds to Hostile Bid
Aurora confirmed receipt of Curaleaf's unsolicited takeover bid at US$4.00 per share, consisting of 0.3463 Curaleaf shares plus US$0.75 cash, with a cap of US$5.00 per Aurora share.
-
Prior Proposals Disclosed
Aurora received letters from Curaleaf dated June 23 and July 7, 2026; only the July 7 letter included financial terms, and it did not detail the cash/share mix.
-
Consideration Cap Below Recent Trading
The US$5.00 cap is lower than Aurora's trading price as recently as December 18, 2025, suggesting the bid may undervalue the company.
-
Board Forms Special Committee
Aurora's board will form a special committee of independent directors to consider the proposal; no decision has been made and shareholders need take no action.
Analysis · ACB · Life Sciences
Aurora's response to Curaleaf's unsolicited takeover bid adds material new details: the company received two prior letters from Curaleaf (June 23 and July 7), only the July 7 letter included financial terms, and the current proposal includes a US$5.00 cap on consideration — lower than Aurora's trading price as recently as December 18, 2025. The board will form a special committee, and the lead independent director has been in contact with Curaleaf's CEO as recently as July 24. This context suggests the bid may be opportunistic and undervalues Aurora, while the board is taking a deliberate process. The stock trades at $3.84 today, below the $4.00 offer, but the cap and prior engagement history are key for shareholders evaluating the bid.
At the time of this filing, ACB was trading at $3.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $249.1M. The 52-week trading range was $2.56 to $6.67. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.